Readoutin 14d
Hangzhou Highlightll Pharmaceutical Co., Ltd — TLL-018
Phase 3 primary completion: A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Rheumatoid Arthritis
Readoutin 14d
Phase 3 primary completion: A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.